TABLE 3.
| Characteristic | 1970-1979 | 1980-1989 | 1990-1999 | 2000-2009 | P Value |
|---|---|---|---|---|---|
| Age at diagnosis, mean (median; range), y | 26.6 (24.5; 19-36) | 30.4 (31.5; 19-39) | 30.4 (31; 18-39) | 29.8 (29; 19-39) | .09 |
| Breslow mean (median; range), mm (n=202) | 0.44 (0.47; 0.18-0.70) | 0.83 (0.58; 0.15-3.20) | 0.89 (0.58; 0.11-5.00) | 0.80 (0.47; 0.20-19.70) | .12 |
| Sex (N=256) | .90 | ||||
| Female | 10/16 (63) | 30/44 (68) | 47/67 (70) | 92/129 (71) | |
| Male | 6/16 (37) | 14/44 (32) | 20/67 (30) | 37/129 (29) | |
| Site (n=255) | .02 | ||||
| Lower extremity | 2/16 (13) | 16/43 (37) | 14/67 (21) | 31/129 (24) | |
| Back | 1/16 (6) | 4/43 (9) | 12/67 (18) | 40/129 (31) | |
| Upper extremity | 4/16 (25) | 8/43 (19) | 12/67 (18) | 25/129 (19) | |
| Neck, shoulder | 3/16 (19) | 5/43 (12) | 8/67 (12) | 8/129 (6) | |
| Chest, breast | 1/16 (6) | 3/43 (7) | 6/67 (9) | 11/129 (9) | |
| Head | 3/16 (19) | 5/43 (12) | 6/67 (9) | 5/129 (4) | |
| Abdomen | 1/16 (6) | 2/43 (5) | 4/67 (6) | 9/129 (7) | |
| Foot | 1/16 (6) | 0/43 | 5/67 (7) | 0/129 | |
| Location (n=254) | .54 | ||||
| Left | 8/15 (53) | 25/43 (58) | 28/67 (42) | 61/129 (47) | |
| Right | 5/15 (33) | 17/43 (40) | 32/67 (48) | 57/129 (44) | |
| Central | 2/15 (13) | 1/43 (2) | 7/67 (10) | 11/129 (9) | |
| Breslow thickness, mm (n=202) | .27 | ||||
| ≤1.00 | 6/6 (100) | 31/40 (78) | 38/51 (75) | 92/105 (88) | |
| 1.01-2.00 | 0/6 | 5/40 (13) | 8/51 (16) | 10/105 (10) | |
| 2.01-4.00 | 0/6 | 4/40 (10) | 4/51 (8) | 1/105 (1) | |
| >4.00 | 0/6 | 0/40 | 1/51 (2) | 2/105 (2) | |
| Histogenic type (n=223) | .05 | ||||
| SS | 5/9 (56) | 28/40 (70) | 39/60 (65) | 83/114 (73) | |
| MIS | 1/9 (11) | 3/40 (8) | 17/60 (28) | 24/114 (21) | |
| Nodular | 2/9 (22) | 6/40 (15) | 3/60 (5) | 4/114 (4) | |
| Spitzoid | 1/9 (11) | 2/40 (5) | 1/60 (2) | 2/114 (2) | |
| Acral lentiginous | 0/9 | 0/40 | 0/60 | 1/114 (1) | |
| Lentigo maligna | 0/9 | 1/40 (3) | 0/60 | 0/114 | |
| Pathologic stage (n=250) | .006 | ||||
| 0 | 2/14 (14) | 3/41 (7) | 16/66 (24) | 24/129 (19) | |
| IA | 8/14 (57) | 28/41 (68) | 37/66 (56) | 88/129 (68) | |
| IB | 2/14 (14) | 3/41 (7) | 3/66 (5) | 12/129 (9) | |
| IIA | 0/14 | 3/41 (7) | 2/66 (3) | 2/129 (2) | |
| IIB | 0/14 | 0/41 | 0/66 | 1/129 (1) | |
| IIIA | 0/14 | 0/41 | 1/66 (2) | 1/129 (1) | |
| IIIB | 0/14 | 1/41 (2) | 0/66 | 0/129 | |
| IIIC | 1/14 (7) | 0/41 | 0/66 | 0/129 | |
| IV | 1/14 (7) | 3/41 (7) | 7/66 (11) | 1/129 (1) | |
| Overall stage (n=250) | .007 | ||||
| I | 12/14 (86) | 34/41 (83) | 56/66 (85) | 124/129 (96) | |
| II, III, or IV | 2/14 (14) | 7/41 (17) | 10/66 (15) | 5/129 (4) | |
| Disease type (n=250) | .17 | ||||
| Noninvasive | 2/14 (14) | 3/41 (7) | 16/66 (24) | 24/129 (19) | |
| Invasive | 12/14 (86) | 38/41 (93) | 50/66 (76) | 105/129 (81) |
a
MIS = melanoma in situ; SS = superficial spreading.
b
Data are presented as No. (percentage) unless indicated otherwise.